Skip to main content

Advertisement

Table 2 Demographic and clinical characteristics of interviewed patients to be inserted

From: Patients’ experience of recurrent/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: a qualitative study

Characteristic Total, n (%) N = 14
Gender, n (%)
 Male 10 (71)
 Female 4 (29)
Age range, years, n (%)a
  < 55 2 (14)
 55–64 7 (50)
 65–74 3 (21)
 75–84 2 (14)
Ethnicity, n (%)
 Caucasian or white 14 (100)
Education, n (%)a
 Bachelor/graduate degree or higher 10 (71)
 High school diploma or equivalent 3 (21)
 Missing data 1 (7)
Work status, n (%)
 Full/part- time paid 7 (50)
 Retired 4 (29)
 Other 3 (21)
Tumour Location, n (%)a
 Oral cavity 6 (43)
 Larynx 2 (14)
 Oropharynx 3 (21)
 Hypopharynx 2 (14)
 Nasopharynx 1 (7)
Cancer status, n (%)
 Metastatic 10 (71)
 Recurrent 4 (29)
Tumour progression during or after treatment
 Yes 4 (29)
 No 10 (71)
WHO performance status, n (%)b
 0 7 (50)
 1 7 (50)
Time since diagnosis, n (%)
 3–6 months 1 (7)
 Within last 12 months 2 (14)
 1–2 years 7 (50)
  > 2 years 4 (29)
Treatment history, n (%)
 Surgery only 1 (7)
 Chemotherapy and radiation 6 (43)
 Radiation, chemotherapy and surgery 7 (50)
 Additional treatmentsc 2 (14)
Comorbidities, n (%)
 Hypertension 3 (21)
 Heart disease 2 (14)
 Respiratory disease 1 (7)
 Cancer (other than H&N) 1 (7)
 Other 2 (14)
  1. Abbreviations: H&N head and neck. WHO World Health Organization
  2. aPercentages do not total 100% due to rounding
  3. bWHO performance status 0 = fully active, able to carry on all pre-disease performance without restriction; WHO performance status 1 = restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work)
  4. cAdditional treatments were: immunotherapy; pembrolizuamb or nivolumab